Diabetes drugs may shield against severe pneumonia outcomes

NCT ID NCT07708610

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study looks at whether taking a combination of GLP-1 receptor agonists and SGLT2 inhibitors before being hospitalized with pneumonia improves early outcomes in adults with type 2 diabetes. Researchers analyzed health records from over 70,000 patients, comparing those on both drugs to those on one or neither. The goal is to see if these medications reduce the risk of death, need for a breathing machine, or kidney replacement therapy within 30 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GLP-1 receptor agonists and SGLT2 inhibitors (glucose-lowering drugs)
What this could lead to
If these drugs improve pneumonia outcomes, it could point to better treatment strategies for people with type 2 diabetes hospitalized with pneumonia.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. The findings need confirmation in prospective studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chung Shan Medical University Hospital

    Taichung, Taichung, 402, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.